Literature DB >> 14959867

Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase.

Semra Paydas, Sinan Yavuz, Umut Disel, Berksoy Sahin, Melek Ergin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14959867     DOI： 10.1080/1042819031000123555

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  4 in total

Review 1.  Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review.

Authors:  Peter Valent; Klaus Lechner
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

2.  Use of rituximab in autoimmune hemolytic anemia associated with non-hodgkin lymphomas.

Authors:  Claudio Fozza; Maurizio Longinotti
Journal:  Adv Hematol       Date:  2011-04-10

3.  Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.

Authors:  Christina Kalpadakis; Gerassimos A Pangalis; Maria K Angelopoulou; Sotirios Sachanas; Flora N Kontopidou; Xanthi Yiakoumis; Stella I Kokoris; Evagelia M Dimitriadou; Maria N Dimopoulou; Maria Moschogiannis; Penelope Korkolopoulou; Marie-Christine Kyrtsonis; Marina P Siakantaris; Theodora Papadaki; Panayiotis Tsaftaridis; Eleni Plata; Helen E Papadaki; Theodoros P Vassilakopoulos
Journal:  Oncologist       Date:  2013-01-23

Review 4.  Non-gastric marginal zone B-cell lymphoma in Korea: clinical features, treatment, and prognostic factors.

Authors:  Sung Yong Oh; Cheolwon Suh
Journal:  Korean J Intern Med       Date:  2010-08-31       Impact factor: 3.165
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.